At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SIGA SIGA Technologies Inc.
Market Closed 12-20 16:00:00 EST
5.91
-0.12
-1.99%
盘后5.89
-0.02-0.34%
19:38 EST
High6.05Low5.71Vol540.94K
Open5.88D1 Closing6.03Amplitude5.64%
Mkt Cap422.00MTradable Cap238.53MTotal Shares71.40M
T/O3.20MT/O Rate1.34%Tradable Shares40.36M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Undiscovered Gems In The United States To Explore December 2024
Simply Wall St.  ·  12-20 18:02
Undiscovered Gems In The United States To Explore December 2024
Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?
Zacks  ·  12-11
Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?
BRIEF-Interim Results From Stomp Study Of Siga’S Tecovirimat In Treatment Of Mpox Announced
Reuters  ·  12-11
BRIEF-Interim Results From Stomp Study Of Siga’S Tecovirimat In Treatment Of Mpox Announced
UPDATE 1-Siga's mpox drug did not improve lesion resolution or pain, NIH study finds
Reuters  ·  12-11
UPDATE 1-Siga's mpox drug did not improve lesion resolution or pain, NIH study finds
SIGA Technologies Inc - Study Stopped Enrolling Patients in All Study Arms
THOMSON REUTERS  ·  12-11
SIGA Technologies Inc - Study Stopped Enrolling Patients in All Study Arms
Interim Results From Stomp Study of SIGA’s Tecovirimat in Treatment of Mpox Announced
THOMSON REUTERS  ·  12-11
Interim Results From Stomp Study of SIGA’s Tecovirimat in Treatment of Mpox Announced
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced
GlobeNewswire  ·  12-11
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced
Nih: Nih Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain - Website
THOMSON REUTERS  ·  12-11
Nih: Nih Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain - Website
Nih: Data Safety and Monitoring Board Recommended Stopping Further Enrollment of Participants Who Were Being Randomized to Tecovirimat or Placebo
THOMSON REUTERS  ·  12-11
Nih: Data Safety and Monitoring Board Recommended Stopping Further Enrollment of Participants Who Were Being Randomized to Tecovirimat or Placebo
NIH study finds Siga’s tecovirimat did not improve Mpox resolution or pain
TIPRANKS  ·  12-11
NIH study finds Siga’s tecovirimat did not improve Mpox resolution or pain
Should Value Investors Buy Siga Technologies (SIGA) Stock?
Zacks  ·  12-09
Should Value Investors Buy Siga Technologies (SIGA) Stock?
Siga Technologies (SIGA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zacks  ·  12-05
Siga Technologies (SIGA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Why SIGA Technologies (SIGA) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
Insider Monkey  ·  12-01
Why SIGA Technologies (SIGA) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket
seekingalpha  ·  11-22
SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket
Are Investors Undervaluing Siga Technologies (SIGA) Right Now?
Zacks  ·  11-21
Are Investors Undervaluing Siga Technologies (SIGA) Right Now?
Impressive Earnings May Not Tell The Whole Story For SIGA Technologies (NASDAQ:SIGA)
Simply Wall St.  ·  11-15
Impressive Earnings May Not Tell The Whole Story For SIGA Technologies (NASDAQ:SIGA)
SIGA Technologies Third Quarter 2024 Earnings: EPS: US$0.019 (vs US$0.006 loss in 3Q 2023)
Simply Wall St.  ·  11-09
SIGA Technologies Third Quarter 2024 Earnings: EPS: US$0.019 (vs US$0.006 loss in 3Q 2023)
SIGA Technologies Inc (SIGA) Q3 2024 Earnings Call Highlights: Strong Procurement Orders and ...
GuruFocus.com  ·  11-08
SIGA Technologies Inc (SIGA) Q3 2024 Earnings Call Highlights: Strong Procurement Orders and ...
SIGA Technologies Q3 EPS $0.02 Up From $(0.01) YoY, Sales $10.00M Up From $9.23M YoY
Benzinga  ·  11-08
SIGA Technologies Q3 EPS $0.02 Up From $(0.01) YoY, Sales $10.00M Up From $9.23M YoY
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024
THOMSON REUTERS  ·  11-08
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024

Introduction

Company Name.
SIGA Technologies Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Issue price:
--